nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—NR5A1—Vinblastine—testicular cancer	0.345	0.615	CbGbCtD
Cladribine—ABCG2—Dactinomycin—testicular cancer	0.0415	0.074	CbGbCtD
Cladribine—SLC22A2—Vinblastine—testicular cancer	0.0352	0.0628	CbGbCtD
Cladribine—SLC22A2—Cisplatin—testicular cancer	0.0323	0.0576	CbGbCtD
Cladribine—ABCG2—Carboplatin—testicular cancer	0.0279	0.0497	CbGbCtD
Cladribine—NR5A1—corpus luteum—testicular cancer	0.0274	0.214	CbGeAlD
Cladribine—ABCG2—Cisplatin—testicular cancer	0.0238	0.0425	CbGbCtD
Cladribine—ABCG2—Etoposide—testicular cancer	0.0234	0.0418	CbGbCtD
Cladribine—NR5A1—seminiferous tubule of testis—testicular cancer	0.0233	0.181	CbGeAlD
Cladribine—NR5A1—Ovarian Infertility Genes—DAZL—testicular cancer	0.0187	0.184	CbGpPWpGaD
Cladribine—NR5A1—Transcriptional regulation of pluripotent stem cells—PRDM14—testicular cancer	0.0168	0.166	CbGpPWpGaD
Cladribine—ABCG2—Doxorubicin—testicular cancer	0.016	0.0285	CbGbCtD
Cladribine—ABCG2—Methotrexate—testicular cancer	0.0155	0.0276	CbGbCtD
Cladribine—POLE4—embryo—testicular cancer	0.00617	0.0481	CbGeAlD
Cladribine—POLE2—embryo—testicular cancer	0.0054	0.042	CbGeAlD
Cladribine—POLE2—Global Genomic NER (GG-NER)—ERCC4—testicular cancer	0.00432	0.0426	CbGpPWpGaD
Cladribine—POLE2—Global Genomic NER (GG-NER)—ERCC1—testicular cancer	0.00378	0.0372	CbGpPWpGaD
Cladribine—POLE2—Transcription-coupled NER (TC-NER)—ERCC4—testicular cancer	0.00345	0.034	CbGpPWpGaD
Cladribine—POLE2—Nucleotide Excision Repair—ERCC4—testicular cancer	0.00318	0.0313	CbGpPWpGaD
Cladribine—POLE2—Transcription-coupled NER (TC-NER)—ERCC1—testicular cancer	0.00302	0.0297	CbGpPWpGaD
Cladribine—POLE3—embryo—testicular cancer	0.003	0.0233	CbGeAlD
Cladribine—POLE2—female gonad—testicular cancer	0.00298	0.0232	CbGeAlD
Cladribine—RRM2B—seminal vesicle—testicular cancer	0.00298	0.0232	CbGeAlD
Cladribine—POLE3—seminal vesicle—testicular cancer	0.00281	0.0219	CbGeAlD
Cladribine—POLE—Global Genomic NER (GG-NER)—ERCC4—testicular cancer	0.00279	0.0274	CbGpPWpGaD
Cladribine—POLE2—Nucleotide Excision Repair—ERCC1—testicular cancer	0.00278	0.0273	CbGpPWpGaD
Cladribine—POLE2—testis—testicular cancer	0.00264	0.0206	CbGeAlD
Cladribine—POLE—Global Genomic NER (GG-NER)—ERCC1—testicular cancer	0.00243	0.024	CbGpPWpGaD
Cladribine—POLE—embryo—testicular cancer	0.00228	0.0178	CbGeAlD
Cladribine—POLE—Transcription-coupled NER (TC-NER)—ERCC4—testicular cancer	0.00223	0.0219	CbGpPWpGaD
Cladribine—POLE—seminal vesicle—testicular cancer	0.00215	0.0167	CbGeAlD
Cladribine—POLE—Nucleotide Excision Repair—ERCC4—testicular cancer	0.00205	0.0201	CbGpPWpGaD
Cladribine—POLE3—gonad—testicular cancer	0.00203	0.0158	CbGeAlD
Cladribine—NR5A1—gonad—testicular cancer	0.00197	0.0153	CbGeAlD
Cladribine—POLE—Transcription-coupled NER (TC-NER)—ERCC1—testicular cancer	0.00195	0.0192	CbGpPWpGaD
Cladribine—POLE2—lymph node—testicular cancer	0.00191	0.0149	CbGeAlD
Cladribine—PNP—female gonad—testicular cancer	0.00188	0.0147	CbGeAlD
Cladribine—RRM2—embryo—testicular cancer	0.00188	0.0147	CbGeAlD
Cladribine—POLA1—seminal vesicle—testicular cancer	0.00185	0.0144	CbGeAlD
Cladribine—POLE—Nucleotide Excision Repair—ERCC1—testicular cancer	0.00179	0.0176	CbGpPWpGaD
Cladribine—RRM2B—female gonad—testicular cancer	0.00175	0.0136	CbGeAlD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00174	0.0171	CbGpPWpGaD
Cladribine—POLE2—DNA Repair—ERCC4—testicular cancer	0.00165	0.0163	CbGpPWpGaD
Cladribine—POLE3—female gonad—testicular cancer	0.00165	0.0129	CbGeAlD
Cladribine—NR5A1—female gonad—testicular cancer	0.0016	0.0125	CbGeAlD
Cladribine—POLE—gonad—testicular cancer	0.00155	0.0121	CbGeAlD
Cladribine—RRM2B—testis—testicular cancer	0.00155	0.0121	CbGeAlD
Cladribine—SLC28A3—female gonad—testicular cancer	0.00155	0.012	CbGeAlD
Cladribine—RRM1—seminal vesicle—testicular cancer	0.00147	0.0114	CbGeAlD
Cladribine—POLE3—testis—testicular cancer	0.00147	0.0114	CbGeAlD
Cladribine—POLE2—DNA Repair—ERCC1—testicular cancer	0.00145	0.0142	CbGpPWpGaD
Cladribine—NR5A1—testis—testicular cancer	0.00142	0.0111	CbGeAlD
Cladribine—NR5A1—Developmental Biology—PRDM14—testicular cancer	0.00135	0.0133	CbGpPWpGaD
Cladribine—RRM2—gonad—testicular cancer	0.00128	0.00995	CbGeAlD
Cladribine—POLE—female gonad—testicular cancer	0.00126	0.00982	CbGeAlD
Cladribine—DCK—embryo—testicular cancer	0.00121	0.00946	CbGeAlD
Cladribine—POLE2—Telomere Maintenance—H2AFZ—testicular cancer	0.00121	0.0119	CbGpPWpGaD
Cladribine—DCK—seminal vesicle—testicular cancer	0.00114	0.00888	CbGeAlD
Cladribine—RRM2B—lymph node—testicular cancer	0.00112	0.00875	CbGeAlD
Cladribine—POLE—testis—testicular cancer	0.00112	0.00871	CbGeAlD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.00111	0.0109	CbGpPWpGaD
Cladribine—POLA1—female gonad—testicular cancer	0.00109	0.00846	CbGeAlD
Cladribine—POLE—DNA Repair—ERCC4—testicular cancer	0.00107	0.0105	CbGpPWpGaD
Cladribine—POLE3—lymph node—testicular cancer	0.00106	0.00827	CbGeAlD
Cladribine—RRM1—gonad—testicular cancer	0.00106	0.00827	CbGeAlD
Cladribine—RRM2—female gonad—testicular cancer	0.00104	0.00809	CbGeAlD
Cladribine—POLE2—Chromosome Maintenance—H2AFZ—testicular cancer	0.00101	0.00991	CbGpPWpGaD
Cladribine—POLA1—testis—testicular cancer	0.000963	0.00751	CbGeAlD
Cladribine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000951	0.00936	CbGpPWpGaD
Cladribine—POLE—DNA Repair—ERCC1—testicular cancer	0.000931	0.00917	CbGpPWpGaD
Cladribine—RRM2—testis—testicular cancer	0.000921	0.00717	CbGeAlD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000903	0.00889	CbGpPWpGaD
Cladribine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000886	0.00872	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000884	0.0087	CbGpPWpGaD
Cladribine—RRM1—female gonad—testicular cancer	0.000862	0.00672	CbGeAlD
Cladribine—DCK—gonad—testicular cancer	0.000824	0.00642	CbGeAlD
Cladribine—POLE—lymph node—testicular cancer	0.00081	0.00631	CbGeAlD
Cladribine—POLE2—Teniposide—Etoposide—testicular cancer	0.000795	0.166	CbGdCrCtD
Cladribine—POLE—Telomere Maintenance—H2AFZ—testicular cancer	0.000779	0.00766	CbGpPWpGaD
Cladribine—RRM1—testis—testicular cancer	0.000765	0.00596	CbGeAlD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000743	0.00732	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000713	0.00702	CbGpPWpGaD
Cladribine—POLA1—lymph node—testicular cancer	0.000698	0.00544	CbGeAlD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000695	0.00684	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—MMP2—testicular cancer	0.000689	0.00678	CbGpPWpGaD
Cladribine—DCK—female gonad—testicular cancer	0.00067	0.00522	CbGeAlD
Cladribine—RRM2—lymph node—testicular cancer	0.000667	0.0052	CbGeAlD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000658	0.00648	CbGpPWpGaD
Cladribine—POLE—Chromosome Maintenance—H2AFZ—testicular cancer	0.000649	0.00639	CbGpPWpGaD
Cladribine—ABCG2—seminal vesicle—testicular cancer	0.000636	0.00496	CbGeAlD
Cladribine—RRM2—Vinorelbine—Vinblastine—testicular cancer	0.000632	0.132	CbGdCrCtD
Cladribine—DCK—testis—testicular cancer	0.000594	0.00463	CbGeAlD
Cladribine—POLA1—Telomere Maintenance—H2AFZ—testicular cancer	0.000555	0.00546	CbGpPWpGaD
Cladribine—RRM1—lymph node—testicular cancer	0.000554	0.00432	CbGeAlD
Cladribine—POLE2—Mitotic M-M/G1 phases—MAD1L1—testicular cancer	0.000548	0.00539	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000508	0.005	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000478	0.00471	CbGpPWpGaD
Cladribine—POLA1—Chromosome Maintenance—H2AFZ—testicular cancer	0.000462	0.00455	CbGpPWpGaD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000432	0.00425	CbGpPWpGaD
Cladribine—DCK—lymph node—testicular cancer	0.000431	0.00335	CbGeAlD
Cladribine—NR5A1—Gene Expression—DNMT3L—testicular cancer	0.000425	0.00419	CbGpPWpGaD
Cladribine—POLE2—Idarubicin—Epirubicin—testicular cancer	0.000414	0.0864	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Epirubicin—testicular cancer	0.000414	0.0864	CbGdCrCtD
Cladribine—POLE2—Doxorubicin—Epirubicin—testicular cancer	0.000414	0.0864	CbGdCrCtD
Cladribine—POLE2—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.00041	0.00403	CbGpPWpGaD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000403	0.00396	CbGpPWpGaD
Cladribine—POLE2—Idarubicin—Doxorubicin—testicular cancer	0.000383	0.08	CbGdCrCtD
Cladribine—POLE2—Epirubicin—Doxorubicin—testicular cancer	0.000383	0.08	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Doxorubicin—testicular cancer	0.000383	0.08	CbGdCrCtD
Cladribine—POLE2—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000382	0.00376	CbGpPWpGaD
Cladribine—ABCG2—female gonad—testicular cancer	0.000374	0.00291	CbGeAlD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000371	0.00365	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MAD1L1—testicular cancer	0.000366	0.00361	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—MAD1L1—testicular cancer	0.000353	0.00348	CbGpPWpGaD
Cladribine—ABCG2—testis—testicular cancer	0.000331	0.00258	CbGeAlD
Cladribine—PNP—Daunorubicin—Epirubicin—testicular cancer	0.00032	0.0667	CbGdCrCtD
Cladribine—PNP—Daunorubicin—Doxorubicin—testicular cancer	0.000296	0.0617	CbGdCrCtD
Cladribine—POLE2—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000286	0.00281	CbGpPWpGaD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000276	0.00272	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000275	0.00271	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000269	0.00265	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000264	0.0026	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—H2AFZ—testicular cancer	0.000255	0.00252	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—MAD1L1—testicular cancer	0.000252	0.00248	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000246	0.00242	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MAD1L1—testicular cancer	0.000246	0.00242	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—HPGDS—testicular cancer	0.000246	0.00242	CbGpPWpGaD
Cladribine—ABCG2—lymph node—testicular cancer	0.00024	0.00187	CbGeAlD
Cladribine—POLE—Cell Cycle—MAD1L1—testicular cancer	0.000236	0.00232	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000222	0.00218	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00022	0.00216	CbGpPWpGaD
Cladribine—PNP—Metabolism—HPGDS—testicular cancer	0.000213	0.0021	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000205	0.00201	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000192	0.00189	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000188	0.00185	CbGpPWpGaD
Cladribine—DCK—Doxorubicin—Epirubicin—testicular cancer	0.000187	0.0389	CbGdCrCtD
Cladribine—POLE—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000184	0.00181	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—STK11—testicular cancer	0.000179	0.00176	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000175	0.00173	CbGpPWpGaD
Cladribine—DCK—Epirubicin—Doxorubicin—testicular cancer	0.000173	0.036	CbGdCrCtD
Cladribine—RRM2—Cell Cycle—H2AFZ—testicular cancer	0.000172	0.00169	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MAD1L1—testicular cancer	0.000168	0.00166	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—H2AFZ—testicular cancer	0.000165	0.00162	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MMP2—testicular cancer	0.000162	0.00159	CbGpPWpGaD
Cladribine—PNP—Metabolism—STK11—testicular cancer	0.000155	0.00152	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—H2AFZ—testicular cancer	0.000149	0.00147	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000131	0.00129	CbGpPWpGaD
Cladribine—RRM1—Metabolism—HPGDS—testicular cancer	0.000122	0.00121	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—H2AFZ—testicular cancer	0.000117	0.00115	CbGpPWpGaD
Cladribine—Epistaxis—Methotrexate—testicular cancer	0.000104	0.000508	CcSEcCtD
Cladribine—Pneumonia—Epirubicin—testicular cancer	0.000104	0.000507	CcSEcCtD
Cladribine—Nausea—Bleomycin—testicular cancer	0.000103	0.000504	CcSEcCtD
Cladribine—Infestation—Epirubicin—testicular cancer	0.000103	0.000504	CcSEcCtD
Cladribine—Infestation NOS—Epirubicin—testicular cancer	0.000103	0.000504	CcSEcCtD
Cladribine—Vomiting—Dactinomycin—testicular cancer	0.000103	0.000503	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000102	0.000499	CcSEcCtD
Cladribine—Rash—Dactinomycin—testicular cancer	0.000102	0.000499	CcSEcCtD
Cladribine—Decreased appetite—Etoposide—testicular cancer	0.000102	0.000498	CcSEcCtD
Cladribine—Diarrhoea—Ifosfamide—testicular cancer	0.000101	0.000496	CcSEcCtD
Cladribine—Pancytopenia—Doxorubicin—testicular cancer	0.000101	0.000496	CcSEcCtD
Cladribine—Renal failure—Epirubicin—testicular cancer	0.000101	0.000495	CcSEcCtD
Cladribine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000101	0.000495	CcSEcCtD
Cladribine—Body temperature increased—Cisplatin—testicular cancer	0.000101	0.000494	CcSEcCtD
Cladribine—Fatigue—Etoposide—testicular cancer	0.000101	0.000494	CcSEcCtD
Cladribine—RRM2—Metabolism—HPGDS—testicular cancer	0.000101	0.000993	CbGpPWpGaD
Cladribine—Constipation—Etoposide—testicular cancer	0.0001	0.00049	CcSEcCtD
Cladribine—Pain—Etoposide—testicular cancer	0.0001	0.00049	CcSEcCtD
Cladribine—Conjunctivitis—Epirubicin—testicular cancer	0.0001	0.00049	CcSEcCtD
Cladribine—Urinary tract infection—Epirubicin—testicular cancer	0.0001	0.00049	CcSEcCtD
Cladribine—Neutropenia—Doxorubicin—testicular cancer	9.99e-05	0.000489	CcSEcCtD
Cladribine—Upper respiratory tract infection—Doxorubicin—testicular cancer	9.93e-05	0.000486	CcSEcCtD
Cladribine—Haemoglobin—Methotrexate—testicular cancer	9.93e-05	0.000486	CcSEcCtD
Cladribine—Haemorrhage—Methotrexate—testicular cancer	9.88e-05	0.000483	CcSEcCtD
Cladribine—Dizziness—Ifosfamide—testicular cancer	9.81e-05	0.00048	CcSEcCtD
Cladribine—Pharyngitis—Methotrexate—testicular cancer	9.8e-05	0.00048	CcSEcCtD
Cladribine—Urinary tract disorder—Methotrexate—testicular cancer	9.75e-05	0.000477	CcSEcCtD
Cladribine—Hepatobiliary disease—Epirubicin—testicular cancer	9.74e-05	0.000476	CcSEcCtD
Cladribine—Epistaxis—Epirubicin—testicular cancer	9.71e-05	0.000475	CcSEcCtD
Cladribine—Urethral disorder—Methotrexate—testicular cancer	9.68e-05	0.000474	CcSEcCtD
Cladribine—Feeling abnormal—Etoposide—testicular cancer	9.65e-05	0.000472	CcSEcCtD
Cladribine—Nausea—Dactinomycin—testicular cancer	9.62e-05	0.00047	CcSEcCtD
Cladribine—Pneumonia—Doxorubicin—testicular cancer	9.58e-05	0.000469	CcSEcCtD
Cladribine—Gastrointestinal pain—Etoposide—testicular cancer	9.58e-05	0.000469	CcSEcCtD
Cladribine—Infestation NOS—Doxorubicin—testicular cancer	9.53e-05	0.000466	CcSEcCtD
Cladribine—Infestation—Doxorubicin—testicular cancer	9.53e-05	0.000466	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	9.45e-05	0.000462	CcSEcCtD
Cladribine—Vomiting—Ifosfamide—testicular cancer	9.43e-05	0.000461	CcSEcCtD
Cladribine—DCK—Metabolism—HPGDS—testicular cancer	9.42e-05	0.000928	CbGpPWpGaD
Cladribine—Hypersensitivity—Cisplatin—testicular cancer	9.42e-05	0.000461	CcSEcCtD
Cladribine—Renal failure—Doxorubicin—testicular cancer	9.37e-05	0.000458	CcSEcCtD
Cladribine—Rash—Ifosfamide—testicular cancer	9.35e-05	0.000457	CcSEcCtD
Cladribine—Dermatitis—Ifosfamide—testicular cancer	9.34e-05	0.000457	CcSEcCtD
Cladribine—Erythema multiforme—Methotrexate—testicular cancer	9.34e-05	0.000457	CcSEcCtD
Cladribine—Urticaria—Etoposide—testicular cancer	9.31e-05	0.000455	CcSEcCtD
Cladribine—Haemoglobin—Epirubicin—testicular cancer	9.29e-05	0.000454	CcSEcCtD
Cladribine—Body temperature increased—Etoposide—testicular cancer	9.26e-05	0.000453	CcSEcCtD
Cladribine—Abdominal pain—Etoposide—testicular cancer	9.26e-05	0.000453	CcSEcCtD
Cladribine—Urinary tract infection—Doxorubicin—testicular cancer	9.26e-05	0.000453	CcSEcCtD
Cladribine—Conjunctivitis—Doxorubicin—testicular cancer	9.26e-05	0.000453	CcSEcCtD
Cladribine—Haemorrhage—Epirubicin—testicular cancer	9.24e-05	0.000452	CcSEcCtD
Cladribine—Eye disorder—Methotrexate—testicular cancer	9.23e-05	0.000452	CcSEcCtD
Cladribine—Asthenia—Cisplatin—testicular cancer	9.18e-05	0.000449	CcSEcCtD
Cladribine—Pharyngitis—Epirubicin—testicular cancer	9.17e-05	0.000449	CcSEcCtD
Cladribine—Cardiac disorder—Methotrexate—testicular cancer	9.17e-05	0.000448	CcSEcCtD
Cladribine—Urinary tract disorder—Epirubicin—testicular cancer	9.13e-05	0.000447	CcSEcCtD
Cladribine—Oedema peripheral—Epirubicin—testicular cancer	9.11e-05	0.000445	CcSEcCtD
Cladribine—Connective tissue disorder—Epirubicin—testicular cancer	9.08e-05	0.000444	CcSEcCtD
Cladribine—Urethral disorder—Epirubicin—testicular cancer	9.06e-05	0.000443	CcSEcCtD
Cladribine—Hepatobiliary disease—Doxorubicin—testicular cancer	9.01e-05	0.000441	CcSEcCtD
Cladribine—Epistaxis—Doxorubicin—testicular cancer	8.99e-05	0.00044	CcSEcCtD
Cladribine—Angiopathy—Methotrexate—testicular cancer	8.96e-05	0.000438	CcSEcCtD
Cladribine—Immune system disorder—Methotrexate—testicular cancer	8.92e-05	0.000436	CcSEcCtD
Cladribine—Mediastinal disorder—Methotrexate—testicular cancer	8.9e-05	0.000435	CcSEcCtD
Cladribine—RRM1—Metabolism—STK11—testicular cancer	8.9e-05	0.000876	CbGpPWpGaD
Cladribine—Chills—Methotrexate—testicular cancer	8.86e-05	0.000434	CcSEcCtD
Cladribine—Nausea—Ifosfamide—testicular cancer	8.81e-05	0.000431	CcSEcCtD
Cladribine—Diarrhoea—Cisplatin—testicular cancer	8.75e-05	0.000428	CcSEcCtD
Cladribine—Erythema multiforme—Epirubicin—testicular cancer	8.74e-05	0.000427	CcSEcCtD
Cladribine—Alopecia—Methotrexate—testicular cancer	8.73e-05	0.000427	CcSEcCtD
Cladribine—Mental disorder—Methotrexate—testicular cancer	8.65e-05	0.000423	CcSEcCtD
Cladribine—Eye disorder—Epirubicin—testicular cancer	8.64e-05	0.000423	CcSEcCtD
Cladribine—Hypersensitivity—Etoposide—testicular cancer	8.63e-05	0.000422	CcSEcCtD
Cladribine—Erythema—Methotrexate—testicular cancer	8.6e-05	0.000421	CcSEcCtD
Cladribine—Malnutrition—Methotrexate—testicular cancer	8.6e-05	0.000421	CcSEcCtD
Cladribine—Haemoglobin—Doxorubicin—testicular cancer	8.6e-05	0.00042	CcSEcCtD
Cladribine—Cardiac disorder—Epirubicin—testicular cancer	8.58e-05	0.00042	CcSEcCtD
Cladribine—Haemorrhage—Doxorubicin—testicular cancer	8.55e-05	0.000418	CcSEcCtD
Cladribine—Pharyngitis—Doxorubicin—testicular cancer	8.49e-05	0.000415	CcSEcCtD
Cladribine—Urinary tract disorder—Doxorubicin—testicular cancer	8.45e-05	0.000413	CcSEcCtD
Cladribine—Oedema peripheral—Doxorubicin—testicular cancer	8.43e-05	0.000412	CcSEcCtD
Cladribine—Asthenia—Etoposide—testicular cancer	8.41e-05	0.000411	CcSEcCtD
Cladribine—Connective tissue disorder—Doxorubicin—testicular cancer	8.4e-05	0.000411	CcSEcCtD
Cladribine—Angiopathy—Epirubicin—testicular cancer	8.39e-05	0.00041	CcSEcCtD
Cladribine—Urethral disorder—Doxorubicin—testicular cancer	8.38e-05	0.00041	CcSEcCtD
Cladribine—Immune system disorder—Epirubicin—testicular cancer	8.35e-05	0.000408	CcSEcCtD
Cladribine—Mediastinal disorder—Epirubicin—testicular cancer	8.33e-05	0.000407	CcSEcCtD
Cladribine—Back pain—Methotrexate—testicular cancer	8.32e-05	0.000407	CcSEcCtD
Cladribine—Chills—Epirubicin—testicular cancer	8.29e-05	0.000406	CcSEcCtD
Cladribine—Pruritus—Etoposide—testicular cancer	8.29e-05	0.000405	CcSEcCtD
Cladribine—Arrhythmia—Epirubicin—testicular cancer	8.26e-05	0.000404	CcSEcCtD
Cladribine—Alopecia—Epirubicin—testicular cancer	8.17e-05	0.0004	CcSEcCtD
Cladribine—Vomiting—Cisplatin—testicular cancer	8.13e-05	0.000398	CcSEcCtD
Cladribine—Mental disorder—Epirubicin—testicular cancer	8.1e-05	0.000396	CcSEcCtD
Cladribine—Erythema multiforme—Doxorubicin—testicular cancer	8.09e-05	0.000396	CcSEcCtD
Cladribine—Rash—Cisplatin—testicular cancer	8.06e-05	0.000394	CcSEcCtD
Cladribine—Dermatitis—Cisplatin—testicular cancer	8.06e-05	0.000394	CcSEcCtD
Cladribine—Erythema—Epirubicin—testicular cancer	8.05e-05	0.000394	CcSEcCtD
Cladribine—Malnutrition—Epirubicin—testicular cancer	8.05e-05	0.000394	CcSEcCtD
Cladribine—Diarrhoea—Etoposide—testicular cancer	8.02e-05	0.000392	CcSEcCtD
Cladribine—Eye disorder—Doxorubicin—testicular cancer	7.99e-05	0.000391	CcSEcCtD
Cladribine—Ill-defined disorder—Methotrexate—testicular cancer	7.98e-05	0.00039	CcSEcCtD
Cladribine—Anaemia—Methotrexate—testicular cancer	7.95e-05	0.000389	CcSEcCtD
Cladribine—Cardiac disorder—Doxorubicin—testicular cancer	7.94e-05	0.000388	CcSEcCtD
Cladribine—Flatulence—Epirubicin—testicular cancer	7.93e-05	0.000388	CcSEcCtD
Cladribine—Back pain—Epirubicin—testicular cancer	7.78e-05	0.000381	CcSEcCtD
Cladribine—Angiopathy—Doxorubicin—testicular cancer	7.76e-05	0.00038	CcSEcCtD
Cladribine—Malaise—Methotrexate—testicular cancer	7.75e-05	0.000379	CcSEcCtD
Cladribine—Dizziness—Etoposide—testicular cancer	7.75e-05	0.000379	CcSEcCtD
Cladribine—Immune system disorder—Doxorubicin—testicular cancer	7.73e-05	0.000378	CcSEcCtD
Cladribine—Mediastinal disorder—Doxorubicin—testicular cancer	7.71e-05	0.000377	CcSEcCtD
Cladribine—Chills—Doxorubicin—testicular cancer	7.67e-05	0.000375	CcSEcCtD
Cladribine—Arrhythmia—Doxorubicin—testicular cancer	7.64e-05	0.000374	CcSEcCtD
Cladribine—Nausea—Cisplatin—testicular cancer	7.6e-05	0.000372	CcSEcCtD
Cladribine—Alopecia—Doxorubicin—testicular cancer	7.56e-05	0.00037	CcSEcCtD
Cladribine—Cough—Methotrexate—testicular cancer	7.5e-05	0.000367	CcSEcCtD
Cladribine—Mental disorder—Doxorubicin—testicular cancer	7.49e-05	0.000367	CcSEcCtD
Cladribine—Ill-defined disorder—Epirubicin—testicular cancer	7.47e-05	0.000365	CcSEcCtD
Cladribine—Vomiting—Etoposide—testicular cancer	7.45e-05	0.000364	CcSEcCtD
Cladribine—Erythema—Doxorubicin—testicular cancer	7.45e-05	0.000364	CcSEcCtD
Cladribine—Malnutrition—Doxorubicin—testicular cancer	7.45e-05	0.000364	CcSEcCtD
Cladribine—Anaemia—Epirubicin—testicular cancer	7.44e-05	0.000364	CcSEcCtD
Cladribine—Rash—Etoposide—testicular cancer	7.39e-05	0.000361	CcSEcCtD
Cladribine—Dermatitis—Etoposide—testicular cancer	7.38e-05	0.000361	CcSEcCtD
Cladribine—Headache—Etoposide—testicular cancer	7.34e-05	0.000359	CcSEcCtD
Cladribine—Flatulence—Doxorubicin—testicular cancer	7.34e-05	0.000359	CcSEcCtD
Cladribine—RRM2—Metabolism—STK11—testicular cancer	7.33e-05	0.000721	CbGpPWpGaD
Cladribine—Chest pain—Methotrexate—testicular cancer	7.32e-05	0.000358	CcSEcCtD
Cladribine—Arthralgia—Methotrexate—testicular cancer	7.32e-05	0.000358	CcSEcCtD
Cladribine—Myalgia—Methotrexate—testicular cancer	7.32e-05	0.000358	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	7.27e-05	0.000356	CcSEcCtD
Cladribine—Malaise—Epirubicin—testicular cancer	7.26e-05	0.000355	CcSEcCtD
Cladribine—Discomfort—Methotrexate—testicular cancer	7.23e-05	0.000354	CcSEcCtD
Cladribine—Back pain—Doxorubicin—testicular cancer	7.2e-05	0.000352	CcSEcCtD
Cladribine—Confusional state—Methotrexate—testicular cancer	7.08e-05	0.000346	CcSEcCtD
Cladribine—Cough—Epirubicin—testicular cancer	7.02e-05	0.000343	CcSEcCtD
Cladribine—Infection—Methotrexate—testicular cancer	6.97e-05	0.000341	CcSEcCtD
Cladribine—Nausea—Etoposide—testicular cancer	6.96e-05	0.00034	CcSEcCtD
Cladribine—Ill-defined disorder—Doxorubicin—testicular cancer	6.91e-05	0.000338	CcSEcCtD
Cladribine—Nervous system disorder—Methotrexate—testicular cancer	6.88e-05	0.000337	CcSEcCtD
Cladribine—Anaemia—Doxorubicin—testicular cancer	6.88e-05	0.000337	CcSEcCtD
Cladribine—Thrombocytopenia—Methotrexate—testicular cancer	6.87e-05	0.000336	CcSEcCtD
Cladribine—Chest pain—Epirubicin—testicular cancer	6.85e-05	0.000335	CcSEcCtD
Cladribine—Myalgia—Epirubicin—testicular cancer	6.85e-05	0.000335	CcSEcCtD
Cladribine—Arthralgia—Epirubicin—testicular cancer	6.85e-05	0.000335	CcSEcCtD
Cladribine—DCK—Metabolism—STK11—testicular cancer	6.85e-05	0.000674	CbGpPWpGaD
Cladribine—Anxiety—Epirubicin—testicular cancer	6.83e-05	0.000334	CcSEcCtD
Cladribine—Skin disorder—Methotrexate—testicular cancer	6.82e-05	0.000333	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	6.8e-05	0.000333	CcSEcCtD
Cladribine—Hyperhidrosis—Methotrexate—testicular cancer	6.78e-05	0.000332	CcSEcCtD
Cladribine—Discomfort—Epirubicin—testicular cancer	6.77e-05	0.000331	CcSEcCtD
Cladribine—Malaise—Doxorubicin—testicular cancer	6.71e-05	0.000328	CcSEcCtD
Cladribine—Anorexia—Methotrexate—testicular cancer	6.69e-05	0.000327	CcSEcCtD
Cladribine—Confusional state—Epirubicin—testicular cancer	6.62e-05	0.000324	CcSEcCtD
Cladribine—Oedema—Epirubicin—testicular cancer	6.57e-05	0.000321	CcSEcCtD
Cladribine—Hypotension—Methotrexate—testicular cancer	6.56e-05	0.000321	CcSEcCtD
Cladribine—Infection—Epirubicin—testicular cancer	6.52e-05	0.000319	CcSEcCtD
Cladribine—Cough—Doxorubicin—testicular cancer	6.5e-05	0.000318	CcSEcCtD
Cladribine—Nervous system disorder—Epirubicin—testicular cancer	6.44e-05	0.000315	CcSEcCtD
Cladribine—Thrombocytopenia—Epirubicin—testicular cancer	6.43e-05	0.000315	CcSEcCtD
Cladribine—Tachycardia—Epirubicin—testicular cancer	6.41e-05	0.000314	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Methotrexate—testicular cancer	6.39e-05	0.000313	CcSEcCtD
Cladribine—Skin disorder—Epirubicin—testicular cancer	6.38e-05	0.000312	CcSEcCtD
Cladribine—Hyperhidrosis—Epirubicin—testicular cancer	6.35e-05	0.000311	CcSEcCtD
Cladribine—Insomnia—Methotrexate—testicular cancer	6.35e-05	0.00031	CcSEcCtD
Cladribine—Arthralgia—Doxorubicin—testicular cancer	6.34e-05	0.00031	CcSEcCtD
Cladribine—Chest pain—Doxorubicin—testicular cancer	6.34e-05	0.00031	CcSEcCtD
Cladribine—Myalgia—Doxorubicin—testicular cancer	6.34e-05	0.00031	CcSEcCtD
Cladribine—Anxiety—Doxorubicin—testicular cancer	6.32e-05	0.000309	CcSEcCtD
Cladribine—Paraesthesia—Methotrexate—testicular cancer	6.3e-05	0.000308	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	6.3e-05	0.000308	CcSEcCtD
Cladribine—Discomfort—Doxorubicin—testicular cancer	6.26e-05	0.000306	CcSEcCtD
Cladribine—Anorexia—Epirubicin—testicular cancer	6.26e-05	0.000306	CcSEcCtD
Cladribine—Dyspnoea—Methotrexate—testicular cancer	6.26e-05	0.000306	CcSEcCtD
Cladribine—Somnolence—Methotrexate—testicular cancer	6.24e-05	0.000305	CcSEcCtD
Cladribine—Hypotension—Epirubicin—testicular cancer	6.14e-05	0.0003	CcSEcCtD
Cladribine—Confusional state—Doxorubicin—testicular cancer	6.13e-05	0.0003	CcSEcCtD
Cladribine—Decreased appetite—Methotrexate—testicular cancer	6.1e-05	0.000298	CcSEcCtD
Cladribine—Oedema—Doxorubicin—testicular cancer	6.08e-05	0.000297	CcSEcCtD
Cladribine—Gastrointestinal disorder—Methotrexate—testicular cancer	6.06e-05	0.000296	CcSEcCtD
Cladribine—Fatigue—Methotrexate—testicular cancer	6.05e-05	0.000296	CcSEcCtD
Cladribine—Infection—Doxorubicin—testicular cancer	6.04e-05	0.000295	CcSEcCtD
Cladribine—Pain—Methotrexate—testicular cancer	6e-05	0.000294	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Epirubicin—testicular cancer	5.98e-05	0.000293	CcSEcCtD
Cladribine—Nervous system disorder—Doxorubicin—testicular cancer	5.96e-05	0.000291	CcSEcCtD
Cladribine—Thrombocytopenia—Doxorubicin—testicular cancer	5.95e-05	0.000291	CcSEcCtD
Cladribine—Insomnia—Epirubicin—testicular cancer	5.94e-05	0.000291	CcSEcCtD
Cladribine—Tachycardia—Doxorubicin—testicular cancer	5.93e-05	0.00029	CcSEcCtD
Cladribine—Skin disorder—Doxorubicin—testicular cancer	5.9e-05	0.000289	CcSEcCtD
Cladribine—Paraesthesia—Epirubicin—testicular cancer	5.9e-05	0.000288	CcSEcCtD
Cladribine—Hyperhidrosis—Doxorubicin—testicular cancer	5.87e-05	0.000287	CcSEcCtD
Cladribine—Dyspnoea—Epirubicin—testicular cancer	5.85e-05	0.000286	CcSEcCtD
Cladribine—Somnolence—Epirubicin—testicular cancer	5.84e-05	0.000286	CcSEcCtD
Cladribine—Anorexia—Doxorubicin—testicular cancer	5.79e-05	0.000283	CcSEcCtD
Cladribine—Feeling abnormal—Methotrexate—testicular cancer	5.78e-05	0.000283	CcSEcCtD
Cladribine—Gastrointestinal pain—Methotrexate—testicular cancer	5.74e-05	0.000281	CcSEcCtD
Cladribine—Decreased appetite—Epirubicin—testicular cancer	5.71e-05	0.000279	CcSEcCtD
Cladribine—Hypotension—Doxorubicin—testicular cancer	5.68e-05	0.000278	CcSEcCtD
Cladribine—Gastrointestinal disorder—Epirubicin—testicular cancer	5.67e-05	0.000277	CcSEcCtD
Cladribine—Fatigue—Epirubicin—testicular cancer	5.66e-05	0.000277	CcSEcCtD
Cladribine—Pain—Epirubicin—testicular cancer	5.62e-05	0.000275	CcSEcCtD
Cladribine—Constipation—Epirubicin—testicular cancer	5.62e-05	0.000275	CcSEcCtD
Cladribine—Urticaria—Methotrexate—testicular cancer	5.57e-05	0.000273	CcSEcCtD
Cladribine—Body temperature increased—Methotrexate—testicular cancer	5.55e-05	0.000271	CcSEcCtD
Cladribine—Abdominal pain—Methotrexate—testicular cancer	5.55e-05	0.000271	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	5.54e-05	0.000271	CcSEcCtD
Cladribine—Insomnia—Doxorubicin—testicular cancer	5.5e-05	0.000269	CcSEcCtD
Cladribine—Paraesthesia—Doxorubicin—testicular cancer	5.46e-05	0.000267	CcSEcCtD
Cladribine—Dyspnoea—Doxorubicin—testicular cancer	5.42e-05	0.000265	CcSEcCtD
Cladribine—Feeling abnormal—Epirubicin—testicular cancer	5.41e-05	0.000265	CcSEcCtD
Cladribine—Somnolence—Doxorubicin—testicular cancer	5.4e-05	0.000264	CcSEcCtD
Cladribine—Gastrointestinal pain—Epirubicin—testicular cancer	5.37e-05	0.000263	CcSEcCtD
Cladribine—Decreased appetite—Doxorubicin—testicular cancer	5.28e-05	0.000258	CcSEcCtD
Cladribine—Gastrointestinal disorder—Doxorubicin—testicular cancer	5.25e-05	0.000257	CcSEcCtD
Cladribine—Fatigue—Doxorubicin—testicular cancer	5.24e-05	0.000256	CcSEcCtD
Cladribine—Urticaria—Epirubicin—testicular cancer	5.22e-05	0.000255	CcSEcCtD
Cladribine—Constipation—Doxorubicin—testicular cancer	5.2e-05	0.000254	CcSEcCtD
Cladribine—Pain—Doxorubicin—testicular cancer	5.2e-05	0.000254	CcSEcCtD
Cladribine—Abdominal pain—Epirubicin—testicular cancer	5.19e-05	0.000254	CcSEcCtD
Cladribine—Body temperature increased—Epirubicin—testicular cancer	5.19e-05	0.000254	CcSEcCtD
Cladribine—Hypersensitivity—Methotrexate—testicular cancer	5.17e-05	0.000253	CcSEcCtD
Cladribine—Asthenia—Methotrexate—testicular cancer	5.03e-05	0.000246	CcSEcCtD
Cladribine—Feeling abnormal—Doxorubicin—testicular cancer	5.01e-05	0.000245	CcSEcCtD
Cladribine—Gastrointestinal pain—Doxorubicin—testicular cancer	4.97e-05	0.000243	CcSEcCtD
Cladribine—Pruritus—Methotrexate—testicular cancer	4.96e-05	0.000243	CcSEcCtD
Cladribine—Hypersensitivity—Epirubicin—testicular cancer	4.84e-05	0.000237	CcSEcCtD
Cladribine—Urticaria—Doxorubicin—testicular cancer	4.83e-05	0.000236	CcSEcCtD
Cladribine—Abdominal pain—Doxorubicin—testicular cancer	4.8e-05	0.000235	CcSEcCtD
Cladribine—Body temperature increased—Doxorubicin—testicular cancer	4.8e-05	0.000235	CcSEcCtD
Cladribine—Diarrhoea—Methotrexate—testicular cancer	4.8e-05	0.000235	CcSEcCtD
Cladribine—Asthenia—Epirubicin—testicular cancer	4.71e-05	0.00023	CcSEcCtD
Cladribine—Pruritus—Epirubicin—testicular cancer	4.65e-05	0.000227	CcSEcCtD
Cladribine—Dizziness—Methotrexate—testicular cancer	4.64e-05	0.000227	CcSEcCtD
Cladribine—Diarrhoea—Epirubicin—testicular cancer	4.49e-05	0.00022	CcSEcCtD
Cladribine—Hypersensitivity—Doxorubicin—testicular cancer	4.48e-05	0.000219	CcSEcCtD
Cladribine—Vomiting—Methotrexate—testicular cancer	4.46e-05	0.000218	CcSEcCtD
Cladribine—Rash—Methotrexate—testicular cancer	4.42e-05	0.000216	CcSEcCtD
Cladribine—Dermatitis—Methotrexate—testicular cancer	4.42e-05	0.000216	CcSEcCtD
Cladribine—Headache—Methotrexate—testicular cancer	4.4e-05	0.000215	CcSEcCtD
Cladribine—Asthenia—Doxorubicin—testicular cancer	4.36e-05	0.000213	CcSEcCtD
Cladribine—Dizziness—Epirubicin—testicular cancer	4.34e-05	0.000212	CcSEcCtD
Cladribine—Pruritus—Doxorubicin—testicular cancer	4.3e-05	0.00021	CcSEcCtD
Cladribine—Vomiting—Epirubicin—testicular cancer	4.18e-05	0.000204	CcSEcCtD
Cladribine—Nausea—Methotrexate—testicular cancer	4.17e-05	0.000204	CcSEcCtD
Cladribine—Diarrhoea—Doxorubicin—testicular cancer	4.16e-05	0.000203	CcSEcCtD
Cladribine—Rash—Epirubicin—testicular cancer	4.14e-05	0.000203	CcSEcCtD
Cladribine—Dermatitis—Epirubicin—testicular cancer	4.14e-05	0.000202	CcSEcCtD
Cladribine—Headache—Epirubicin—testicular cancer	4.11e-05	0.000201	CcSEcCtD
Cladribine—Dizziness—Doxorubicin—testicular cancer	4.02e-05	0.000197	CcSEcCtD
Cladribine—Nausea—Epirubicin—testicular cancer	3.9e-05	0.000191	CcSEcCtD
Cladribine—Vomiting—Doxorubicin—testicular cancer	3.86e-05	0.000189	CcSEcCtD
Cladribine—Rash—Doxorubicin—testicular cancer	3.83e-05	0.000187	CcSEcCtD
Cladribine—Dermatitis—Doxorubicin—testicular cancer	3.83e-05	0.000187	CcSEcCtD
Cladribine—Headache—Doxorubicin—testicular cancer	3.81e-05	0.000186	CcSEcCtD
Cladribine—ABCG2—Metabolism—HPGDS—testicular cancer	3.77e-05	0.000371	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—HPGDS—testicular cancer	3.73e-05	0.000367	CbGpPWpGaD
Cladribine—Nausea—Doxorubicin—testicular cancer	3.61e-05	0.000177	CcSEcCtD
Cladribine—SLC22A1—Metabolism—HPGDS—testicular cancer	3.48e-05	0.000342	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—STK11—testicular cancer	2.74e-05	0.00027	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—STK11—testicular cancer	2.71e-05	0.000267	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—STK11—testicular cancer	2.53e-05	0.000249	CbGpPWpGaD
